PDX Model
Triple Negative Breast Cancer is an aggressive subtype of cancer for which there are minimal treatment options. Studying real human tumors and testing drugs against them is critical for developing new treatments for this disease. Tulane has deep expertise in generating and assessing Patient Derived Xenografts (PDX) of this cancer type, along with corresponding organoids and cell lines.
Publications
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types
View
Engage with Us
Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.
For inquiries, contact:
Elaine Hamm, PhD
Executive in Residence
Email me